Cancer is a worldwide health problem. Last year Spain registered 277,234 cancer diagnoses and this figure is growing. In Catalonia alone, 37,200 new cases were diagnosed last year and this figure is expected to reach 39,000 cases in 2025. This is why, today, on the occasion of World Cancer Day, we are joining the campaign “I am and I will” to showcase our commitment to the fight against this disease.
The Institute for Research in Biomedicine (IRB Barcelona) was founded 15 years ago with the mission to further research into cancer. Today its 450-strong community share a common goal: to contribute to the advance of biomedical sciences and improve quality of life by ensuring...
Each year the Fundación de Investigación del Cáncer de la Universidad de la Salamanca (FICUS) - Centro de Investigación del Cáncer (CIC) presents the 'Doctores Diz Pintado' Prize with the aim to promote and acknowledge the contribution of young Spanish researchers to Cancer Research.
The study infers the genetic changes that coincided with the appearance of different groups of animals and their main traits.
Researchers at IRB Barcelona and BSC-CNS have confirmed that the dynamics of genomic evolution, in addition to the presence or absence of the genes themselves, determines diversity in the animal kingdom.
Published in Nature Ecology and Evolution, the study has been based for the first time on the genomic data of all the large groups of animals.
Ángel Nebreda’s team has published a study in the journal PNAS reporting the involvement of the protein p38 in the progression of lung cancer.
The work shows that patients with low levels of this protein have a better prognosis.
One of the biggest challenges faced by biomedicine is the development of more selective and efficient cancer treatments.
This species shows several genetic duplications, which may explain its high plasticity and capacity to adapt to diverse farming conditions.
CSIC has headed this research, which has brought about a considerable advance in the development of genomic and biotechnological tools to achieve more sustainable fish farming.
The findings of the study will be applied in genetic selection and environmental programming in order to improve fish quality and interaction with the microorganisms present in the host environment.
Nostrum Biodiscovery, a spin-off from IRB Barcelona and the BSC-CNS, focuses on computational simulation to design new drugs and biotech molecules for the market.
The Senén Vilaró Prize is given each year by the “Consejo Social” of the UB and the Bosch i Gimpera Foundation to the best innovative company.
Published in the journal Nature Cancer, the study analyses how genetic alterations in tumour cells prevent the correct degradation of the proteins involved in tumour development and growth, thereby leading to abnormal cell behaviour.
A machine-learning model has allowed the scientists to obtain the most extensive annotation of the ubiquitin-mediated protein degradation system.
The analysis proposes a potential new clinical approach for cancer through the inhibition of oncoproteins with impaired degradation systems.
When you hear the word ‘immunotherapy’, the first thing that comes to mind is that it is a highly effective treatment for cancer. But could it also be the solution or hope for other conditions?
This was precisely the subject addressed at the Barcelona Biomed Conference “Immunotherapy beyond cancer. A cure for age-related diseases”, an event organised by the Institute for Research in Biomedicine (IRB Barcelona) from 18 to 20 November that brought together more than 100 scientists.
Over 3 days, researchers from all over the world have emphasized the potential of this new therapy for other applications. In this regard, Manuel Serrano, ICREA...
Organised by PhD students and postdocs, ENABLE is aimed at the community of young researchers working in biomedicine.
The 3rd ENABLE symposium was held in Nijmegen (the Netherlands) from 13 to 15 November.
The symposium was cofunded by the European Commission and is managed and organised by four research institutes (IRB Barcelona, RIMLS, NNF CPR, and SEMM) and a science communication agency (Scienseed).
Scientists at IRB Barcelona determine the genetic alterations in the cells of cancer patients caused by the main cancer therapies.
This is an important step towards understanding the long-term side effects and optimizing treatments against cancer.
The results have been published in the journal Nature Genetics.